Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Accured Expenses (2016 - 2025)

Apyx Medical's Change in Accured Expenses history spans 15 years, with the latest figure at $553000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 528.41% year-over-year to $553000.0; the TTM value through Dec 2025 reached $209000.0, up 109.22%, while the annual FY2025 figure was $209000.0, 109.22% up from the prior year.
  • Change in Accured Expenses reached $553000.0 in Q4 2025 per APYX's latest filing, up from $79000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q3 2022 to a low of -$2.0 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is $84947.4, with a median of $79000.0 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: surged 1046.85% in 2021, then crashed 5841.67% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.8 million in 2021, then increased by 1.12% to $1.8 million in 2022, then decreased by 21.09% to $1.4 million in 2023, then crashed by 93.84% to $88000.0 in 2024, then soared by 528.41% to $553000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's Change in Accured Expenses are $553000.0 (Q4 2025), $79000.0 (Q3 2025), and $433000.0 (Q2 2025).